GeroQubit is an AI-powered drug discovery platform focused on geroscience and age-related diseases. Unlike conventional molecular generation systems, GeroQubit uses a reaction-first design approach to generate synthesizable small-molecule candidates while integrating target biology, tissue specificity, ADMET prediction, and multi-objective optimization into a unified workflow. The platform helps researchers explore novel compounds with greater emphasis on practical synthesis and biological relevance. Designed for biotechnology companies, pharmaceutical R&D teams, and academic researchers, GeroQubit combines computational chemistry, artificial intelligence, and longevity science to accelerate early-stage therapeutic discovery. GeroQubit is developed by Voxelta Private Limited.